Cancer stem cells: In the line of fire

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 589-598

  Alison, Malcolm R ^a   Lin, Wey Ran ^b   Lim, Susan M L ^c   Nicholson, Linda J ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

ABC transporters; Akt pathway; ALDH; Differentiation therapy; Drug resistance; EMT; Hedgehog signalling; Immunodeficient mice; Irradiation; MicroRNA; Notch signalling; STAT3; Wnt signalling

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL CLONE; CELL RENEWAL; CLONOGENESIS; DIFFERENTIATION THERAPY; DNA DAMAGE; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; STEM CELL NICHE; WNT SIGNALING PATHWAY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84861656466     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.003     Document Type: Review

References (161)

1. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
2. Alison M.R., Lim S., Houghton J.M. Bone marrow-derived cells and epithelial tumours: more than just an inflammatory relationship. Curr Opin Oncol 2009, 21:77-82.
3. Alison M.R., Lim S.M., Nicholson L.J. Cancer stem cells: problems for therapy?. J Pathol 2011, 223:147-161.
4. Quintana E., Shackleton M., Sabel M.S., et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
5. Rountree C.B., Ding W., He L., et al. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem cells 2009, 27:290-299.
6. Zhang M., Behbod F., Atkinson R.L., et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682.
7. Read T.A., Fogarty M.P., Markant S.L., et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
8. Lathia J.D., Gallagher J., Myers J.T., et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 2011, 6:e24807.
9. Shipitsin M., Campbell L.L., Argani P., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
10. Ben-Porath I., Thomson M.W., Carey V.J., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
11. Eppert K., Takenaka K., Lechman E.R., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med 2011, 17:1086-1093.
12. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
13. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
14. Greaves M. Darwin and evolutionary tales in leukemia. The Ham-Wasserman lecture. Hematology Am Soc Hematol Educ Program 2009, 3-12.
15. Greaves M. Cancer stem cells: back to Darwin?. Semin Cancer Biol 2010, 20:65-70.
16. Anderson K., Lutz C., van Delft F.W., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
17. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743.
18. Dieter S.M., Ball C.R., Hoffmann C.M., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
19. Mueller M.T., Hermann P.C., Witthauer J., et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
20. Dylla S.J., Beviglia L., Park I.K., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:e2428.
21. Ma S., Lee T.K., Zheng B.J., et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
22. Levina V., Marrangoni A.M., DeMarco R., et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:e3077.
23. Li X., Lewis M.T., Huang J., Gutierrez C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
24. Alison M.R., Islam S., Wright N.A. Stem cells in cancer: instigators and propagators?. J Cell Sci 2010, 123:2357-2368.
25. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
26. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
27. Koch U., Krause M., Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective. Semin Cancer Biol 2010, 20:116-124.
28. Krause M., Yaromina A., Eicheler W., Koch U., Baumann M. Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin Cancer Res 2011, 17:7224-7229.
29. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
30. Cheng L., Wu Q., Huang Z., et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 2011, 30:800-813.
31. Sarcar B., Kahali S., Prabhu A.H., et al. Targeting radiation-induced G2 checkpoint activation with the Wee-1 Inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011, 10:2405-2414.
32. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008, 22:436-448.
33. Mihatsch J., Toulany M., Bareiss P.M., et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol 2011, 99:300-306.
34. Zhang M., Kleber S., Rohrich M., et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011, 71:7155-7167.
35. Yang Y.P., Chang Y.L., Huang P.I., et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2011, [Apr 18]. 10.1002/jcp. 22,806.
36. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
37. Zielske S.P., Spalding A.C., Wicha M.S., Lawrence T.S. Ablation of breast cancer stem cells with radiation. Transl Oncol 2011, 4:227-233.
38. Yin H., Glass J. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 2011, 6:e24080.
39. Baschnagel A., Russo A., Burgan W.E., et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8:1589-1595.
40. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
41. Beck B., Driessens G., Goossens S., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
42. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
43. Wang L.D., Wagers A.J. Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol 2011, 12:643-655.
44. LaBarge M.A. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010, 16:3121-3129.
45. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
46. Malanchi I., Santamaria-Martinez A., Susanto E., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
47. Shiozawa Y., Pienta K.J., Taichman R.S. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011, 17:5553-5558.
48. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
49. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128:2527-2535.
50. Floor S., van Staveren W.C., Larsimont D., Dumont J.E., Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30:4609-4621.
51. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. Int J Cancer 2011, 129:2310-2314.
52. Martello G., Rosato A., Ferrari F., et al. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
53. Bandyopadhyay A., Wang L., Agyin J., et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5:e10365.
54. Gjerdrum C., Tiron C., Hoiby T., et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010, 107:1124-1129.
55. Gumireddy K., Li A., Gimotty P.A., et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009, 11:1297-1304.
56. Ohashi S., Natsuizaka M., Naganuma S., et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res 2011, 71:6836-6847.
57. van der Horst G., van den Hoogen C., Buijs J.T., et al. Targeting of alpha(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 2011, 13:516-525.
58. Piccirillo S.G., Reynolds B.A., Zanetti N., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
59. Ying M., Wang S., Sang Y., et al. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 2011, 30:3454-3467.
60. Guessous F., Zhang Y., Kofman A., et al. MicroRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010, 9:1031-1036.
61. de Antonellis P., Medaglia C., Cusanelli E., et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 2011, 6:e24584.
62. Silber J., Lim D.A., Petritsch C., et al. MiR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008, 6:14.
63. Wang B., Yu S.C., Jiang J.Y., et al. An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells. Stem Cell Rev 2011, 7:458-470.
64. Ginestier C., Wicinski J., Cervera N., et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009, 8:3297-3302.
65. Pham P.V., Phan N.L., Nguyen N.T., et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011, 9:209.
66. Kodach L.L., Jacobs R.J., Voorneveld P.W., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011, 60:1544-1553.
67. Yamashita T., Honda M., Nio K., et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 2010, 70:4687-4697.
68. Azzi S., Bruno S., Giron-Michel J., et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011, 103:1884-1898.
69. Alison M.R., Guppy N.J., Lim S.M., Nicholson L.J. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?. J Pathol 2010, 222:335-344.
70. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7:292-306.
71. Kakarala M., Brenner D.E., Korkaya H., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010, 122:777-785.
72. Li Y., Zhang T., Korkaya H., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010, 16:2580-2590.
73. Croker A.K., Allan A.L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat 2011, [Epub ahead of print].
74. Kallifatidis G., Rausch V., Baumann B., et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009, 58:949-963.
75. Rausch V., Liu L., Kallifatidis G., et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010, 70:5004-5013.
76. Kim M.P., Fleming J.B., Wang H., et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011, 6:e20636.
77. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011, 89:491-502.
78. Guo Y., Köck K., Ritter C.A., et al. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res 2009, 15:1762-1769.
79. Loebinger M.R., Giangreco A., Groot K.R., et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 2008, 98:380-387.
80. Agarwal S., Hartz A.M., Elmquist W.F., Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 2011, 17:2793-2802.
81. Wang X.Q., Ongkeko W.M., Chen L., et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010, 52:528-539.
82. Lee T.K., Castilho A., Cheung V.C., et al. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53:160-170.
83. Zhang F., Throm S.L., Murley L.L., et al. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol 2011, 82:24-34.
84. Balabanov S., Gontarewicz A., Keller G., et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011, 6:e19164.
85. Cheung S.T., Cheung P.F., Cheng C.K., Wong N.C., Fan S.T. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011, 140:344-355.
86. Zhu Y., Yu F., Jiao Y., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011, 17:7105-7115.
87. Kanwar S.S., Yu Y., Nautiyal J., et al. Difluorinated-curcumin (CDF): a novel potent inhibitor of colon cancer stem-like cells. Pharm Res 2011, 28:827-838.
88. Gangaraju V.K., Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009, 10:116-125.
89. Liu C., Tang D.G. MicroRNA regulation of cancer stem cells. Cancer Res 2011, 71:5950-5954.
90. Wang E., Bhattacharyya S., Szabolcs A., et al. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One 2011, 6:e17918.
91. Yang Y.P., Chien Y., Chiou G.Y., et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33:1462-1476.
92. Bitarte N., Bandres E., Boni V., et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem cells 2011, 29:1661-1671.
93. Barker N., Ridgway R.A., van Es J.H., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
94. Gaston-Massuet C., Andoniadou C.L., Signore M., et al. Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Proc Natl Acad Sci U S A 2011, 108:11482-11487.
95. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
96. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin Cancer Res 2010, 16:3153-3162.
97. Takebe N., Ivy S.P. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res 2010, 16:3106-3112.
98. Pode-Shakked N., Harari-Steinberg O., Haberman-Ziv Y., et al. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 2011, 30:1664-1680.
99. Li Y., Lu W., King T.D., et al. Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation. PLoS One 2010, 5:e11014.
100. Agur Z., Kirnasovsky O.U., Vasserman G., et al. Dickkopf1 regulates fate decision and drives breast cancer stem cells to differentiation: an experimentally supported mathematical model. PLoS One 2011, 6:e24225.
101. King T.D., Suto M.J., Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012, 113:13-18.
102. Gupta P.B., Onder T.T., Jiang G., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
103. Lu D., Choi M.Y., Yu J., et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A 2011, 108:13253-13257.
104. Munz M., Baeuerle P.A., Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-5629.
105. Takezaki T., Hide T., Takanaga H., et al. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci 2011, 102:1306-1312.
106. Peacock C.D., Wang Q., Gesell G.S., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007, 104:4048-4053.
107. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
108. Varnat F., Duquet A., Malerba M., et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009, 1:338-351.
109. Zhang C., Li C., He F., Cai Y., Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol 2011, 137:1679-1686.
110. Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010, 16:3130-3140.
111. Mas C., Ruiz i Altaba A. Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. Biochem Pharmacol 2010, 80:712-723.
112. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011, 11:493-501.
113. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361:1164-1172.
114. Rudin C.M., Hann C.L., Laterra J., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361:1173-1178.
115. Yauch R.L., Dijkgraaf G.J., Alicke B., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
116. LoRusso P.M., Rudin C.M., Reddy J.C., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011, 17:2502-2511.
117. Naka K., Hoshii T., Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010, 101:1577-1581.
118. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 2011, 17:103-112.
119. Feldmann G., Fendrich V., McGovern K., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008, 7:2725-2735.
120. Singh B.N., Fu J., Srivastava R.K., Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011, 6:e27306.
121. Pannuti A., Foreman K., Rizzo P., et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010, 16:3141-3152.
122. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106.
123. Wang Z., Li Y., Ahmad A., et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010, 1806:258-267.
124. Wu Y., Cain-Hom C., Choy L., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
125. Harrison H., Farnie G., Howell S.J., et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70:709-718.
126. Sharma A., Paranjape A.N., Rangarajan A., Dighe R.R. A monoclonal antibody against human notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells. Mol Cancer Ther 2012, 11:77-86.
127. McGowan P.M., Simedrea C., Ribot E.J., et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 2011, 9:834-844.
128. Charles N., Ozawa T., Squatrito M., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6:141-152.
129. Hovinga K.E., Shimizu F., Wang R., et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem cells 2010, 28:1019-1029.
130. Wang J., Wang C., Meng Q., et al. SiRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep 2011, [Jun 12].
131. Fan X., Khaki L., Zhu T.S., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
132. Hoey T., Yen W.C., Axelrod F., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
133. Gurney A., Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc Cell 2011, 3:18.
134. Wang Y., Liu Y., Malek S.N., Zheng P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
135. Martelli A.M., Evangelisti C., Follo M.Y., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 2011, 18:2715-2726.
136. Hill R., Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem 2009, 284:11755-11759.
137. Marinov M., Ziogas A., Pardo O.E., et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009, 15:1277-1287.
138. Korkaya H., Paulson A., Charafe-Jauffret E., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:e1000121.
139. Kahana S., Finniss S., Cazacu S., et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal 2011, 23:1348-1357.
140. Sykes S.M., Lane S.W., Bullinger L., et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011, 146:697-708.
141. Korkaya H., Liu S., Wicha M.S. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res 2011, 17:6125-6129.
142. Nelson E.A., Sharma S.V., Settleman J., Frank D.A. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget 2011, 2:518-524.
143. Hsu H.S., Huang P.I., Chang Y.L., et al. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011, 117:2970-2985.
144. Lin L., Liu Y., Li H., et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 2011, 105:212-220.
145. Marotta L.L., Almendro V., Marusyk A., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 2011, 121:2723-2735.
146. Hellsten R., Johansson M., Dahlman A., Sterner O., Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One 2011, 6:e22118.
147. Lonardo E., Hermann P.C., Mueller M.-T., et al. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011, 9:433-446.
148. Leizer A.L., Alvero A.B., Fu H.H., et al. Regulation of inflammation by the NF-kappaB pathway in ovarian cancer stem cells. Am J Reprod Immunol 2011, 65:438-447.
149. Dayyani F., Gallick G.E., Logothetis C.J., Corn P.G. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011, 103:1665-1675.
150. Dunning N.L., Laversin S.A., Miles A.K., Rees R.C. Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?. Cancer Immunol Immunother 2011, 60:1181-1193.
151. Creighton C.J., Li X., Landis M., Dixon J.M., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009, 106:13820-13825.
152. Simões B.M., Piva M., Iriondo O., et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat 2011, 129:23-35.
153. Tang M., Gonen M., Quintas-Cardama A., et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011, 118:1622-1631.
154. Trumpp A., Essers M., Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 2010, 10:201-209.
155. Bourseau-Guilmain E., Bejaud J., Griveau A., et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm 2012, 423:93-101.
156. Cioffi M., Dorado J., Baeuerle P.A., et al. EpCAM/CD3-bispecific T cell engaging antibody M110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012, 18:465-474.
157. Casagrande F., Cocco E., Bellone S., et al. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 2011, 117:5519-5528.
158. Serrano D., Bleau A.M., Fernandez-Garcia I., et al. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer 2011, 10:96.
159. Joseph I., Tressler R., Bassett E., et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010, 70:9494-9504.
160. Li Y., Wicha M.S., Schwartz S.J., Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 2011, 22:799-806.
161. Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011, 126:355-364.